Reviews
24 December 2013
Vol. 7 No. s8 (2013): The new oral anticoagulants in the Internal Medicine clinical practice
https://doi.org/10.4081/itjm.2013.s8.29

The treatment of venous thromboembolism with new oral anticoagulants

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
venous thromboembolism, new oral anticoagulants, rivaroxaban, apixaban, dabigatran, traditional therapy.
1063
Views
833
Downloads

Authors

Davide Imberti
d.imberti@ausl.pc.it
AUSL Piacenza, Italy.
Traditional anticoagulants, such as low molecular weight heparin, unfractionated heparin, fondaparinux and vitamin K antagonists, have been the mainstay of treatment of venous thromboembolism (VTE) in the clinical hospital setting and after discharge. These anticoagulants are effective, but are associated with some limitations that may lead to their underuse in many settings. Based on the results of large, randomized clinical trials, new oral anticoagulants have been validated for the treatment of acute deep vein thrombosis and pulmonary embolism, and for the prevention of recurrent VTE. These drugs represent a landmark shift in anticoagulation care and may overcome some of the limitations of traditional agents, with the potential of improving adherence to anticoagulation therapy.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



The treatment of venous thromboembolism with new oral anticoagulants. (2013). Italian Journal of Medicine, 7(s8), 29-35. https://doi.org/10.4081/itjm.2013.s8.29

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.